Development Pipeline
We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 34 projects that we review regularly so that we can give priority to the most promising programs.
Pipeline Overview
The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development. Click on a project for further information.
More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.
Number of programs in clinical development.
| Phase | Area | Program (Mode-of-action) | Indication | |
|---|---|---|---|---|
| III | ONC | Darolutamide (AR Inhibitor) | Adjuvant Prostate Cancer |  |
| III | ONC | Darolutamide (AR Inhibitor) | Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy |  |
| III | ONC | Sevabertinib (HER2/mEGFR Inhibitor) | Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02) |  |
| III | CVD | Finerenone (MR Antagonist) | Non-diabetic CKD (FIND-CKD) |  |
| III | CVD | Finerenone (MR Antagonist) | Chronic Kidney Disease in Type 1 Diabetes FINE-ONE | |
| III | CVD | Vericiguat (sGC Stimulator) | Heart Failure (HFrEF) |  |
| III | CVD | Asundexian (FXIa Inhibitor) | 2⁰ Stroke Prevention (OCEANIC Stroke) |  |
| III | Other | Gadoquatrane (High Relaxivity Contrast Agent) | Magnetic Resonance Imaging (HRCA) |  |
| II | ONC | Sevabertinib (HER2/mEGFR Inhibitor) | Metastatic or Unresectable Solid Tumors with HER2-activating Mutations (panSOHO) | |
| II | CVD | Congestive Heart Failure rAAV Gene Therapy (AB-1002) | Congestive Heart Failure (GenePHIT) |  |
| II | CVD | Anti-a2AP | Acute Ischemic Stroke; Pulmonary Embolism |  |
| II | CVD | Nurandociguat (sGC Activator Oral) | Chronic Kidney Disease |  |
| II | NRD | Parkinson's Disease rAAV Gene Therapy (AB-1005) | Parkinson's Disease |  |
| I | ONC | Sevabertinib (HER2/mEGFR Inhibitor) | Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation | |
| I | ONC | DGKzeta Inhibitor | Advanced solid tumors |  |
| I | ONC | Lanerkitug (CCR8 Ab) | Advanced solid tumors |  |
| I | ONC | VVD Keap1 Act | Cancer |  |
| I | ONC | DGKalpha Inhibitor | Cancer |  |
| I | ONC | 225Ac-Pelgifatamab | Advanced Prostate Cancer |  |
| I | ONC | VVD STAT3 Inhibitor | Cancer | |
| I | ONC | 225Ac-PSMA-Trillium | Advanced Prostate Cancer | |
| I | ONC | SOS1 Inhibitor | Advanced Solid Cancers | |
| I | ONC | PRMT5 Inhibitor | MTAP-deleted Solid Tumors | |
| I | ONC | VVD RAS-PI3K Inhibitor | Advanced Solid Tumors | |
| I | ONC | 225Ac-GPC3 | Advanced Liver Cancer | |
| I | CVD | SEMA 3a | Alport Syndrome |  |
| I | CVD | Anti-coagulant | Anti-coagulation |  |
| I | CVD | Atrial fibrillation | Atrial fibrillation |  |
| I | NRD | Bemdaneprocel (Parkinson’s Disease Cell Therapy) | Parkinson's Disease |  |
| I | NRD | Multiple System Atrophy rAAV Gene Therapy | Multiple System Atrophy | |
| I | NRD | Pompe Disease rAAV Gene Therapy | Pompe Disease | |
| I | NRD | LGMD2I/R9 rAAV Gene Therapy | Limb Girdle Muscular Dystrophy | |
| I | Other | GPR84 Antagonist | Diabetic Neuropathic Pain |  |
| I | Other | BAY 2701250 | Pulmonary Hypertension |  |
* Including Precision Cardiovascular, Nephrology & Acute Care
New molecular entity
Life cycle management
